Alexion Pharmaceuticals Inc. wowed investors on its earnings yet again, with second-quarter revenues that soundly beat expectations and prompted the Cheshire, Conn.-based firm to raise for the second time its 2011 sales guidance for paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris (eculizumab).